Psychotic disorders and comorbid substance use disorders: Clinical and therapeutic problems

被引:2
作者
Gouzoulis-Mayfrank E. [1 ]
机构
[1] LVR-Klinik Köln, Akademisches Lehrkrankenhaus der Universität zu Köln, Wilhelm-Griesinger Str. 23, Köln
关键词
Dual diagnosis; Integrative; Psychosis; Substance use disorders; Therapy;
D O I
10.1007/s11757-015-0352-1
中图分类号
学科分类号
摘要
Approximately half of the people with psychotic disorders from the schizophrenia group also develop a comorbid addictive disorder during their lifetime. These so-called dual diagnosis patients (DD) are difficult to treat. They have poor compliance and frequent relapses, they often present with aggressive behavior towards themselves and others and the long-term sociorehabilitative outcomes are poor. In this article the different models for the understanding of the high comorbidity between psychoses and substance use disorders are explained and the principles for an integrated treatment of DD patients are outlined. Low-threshold, motivational, integrated treatment programs with psychoeducative and behavioral therapeutic elements are helpful and should be more extensively implemented; however, long-term treatment methods are needed and therapeutic goals must be realistic and not set too high. © 2015, Springer-Verlag Berlin Heidelberg.
引用
收藏
页码:14 / 20
页数:6
相关论文
共 38 条
[1]  
Baker A.L., Thornton L.K., Hides L., Dunlop A., Treatment of cannabis use among people with psychotic disorders: a critical review of randomised controlled trials, Curr Pharm Des, 18, pp. 4923-4937, (2012)
[2]  
Barrowclough C., Haddock G., Wykes T., Et al., Integrated motivational interviewing and cognitive behavioural therapy for people with psychosis and comorbid substance misuse: randomised controlled trial, BMJ, 341, (2010)
[3]  
Bechdolf A., Pohlmann B., Guttgemanns J., Geyer C., Lindner K., Ferber C., Gouzoulis-Mayfrank E., Stadienabhängige Motivationsbehandlung bei Patienten mit der Doppeldiagnose Psychose und Sucht: ergebnisse einer randomisierten Studie, Nervenarzt, 83, pp. 888-896, (2012)
[4]  
Bennett M.E., Bellack A.S., Gearon J.S., Treating substance abuse in schizophrenia. An initial report, J Subst Abuse Treat, 20, pp. 163-175, (2001)
[5]  
Blanchard J.J., Brown S.A., Horan W.P., Sherwood A.R., Substance use disorders in schizophrenia: review, integration, and a proposed model, Clin Psychol Rev, 20, pp. 207-234, (2000)
[6]  
Brunette M.F., Dawson R., O'Keefe C.D., Et al., A randomized trial of clozapine versus other antipsychotics for cannabis use disorder in patients with schizophrenia, J Dual Diagn, 7, pp. 50-63, (2011)
[7]  
Chambers R.A., Krystal J.H., Self D.W., A neurobiological basis for substance abuse comorbidity in schizophrenia, Biol Psychiatry, 50, pp. 71-83, (2001)
[8]  
Cleary M., Hunt G.E., Matheson S.L., Siegfried N., Walter G., Psychosocial interventions for people with both severe mental illness and substance misuse. The Cochrane Collaboration. Editorial Group: Cochrane Schizophrenia Group, John Wiley & Sons Ltd, (2010)
[9]  
D'Amelio R., Behrendt B.W.T., Psychoedukation Schizophrenie und Sucht. Manual zur Leitung von Patienten- und Angehörigengruppen, (2007)
[10]  
Dixon L., Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes, Schizophr Res, 35, pp. S93-S100, (1999)